Annual report pursuant to Section 13 and 15(d)

Business Combination, Segment Allocation (Details)

v3.10.0.1
Business Combination, Segment Allocation (Details) - USD ($)
$ in Thousands
12 Months Ended
Nov. 30, 2018
Nov. 30, 2017
Nov. 30, 2016
Goodwill $ 15,165 $ 10,684 $ 9,584
CureCell [Member]      
Cash and cash equivalents 58    
Property and equipment, net 1,104    
Inventory 148    
Other assets 300    
Other intangible assets 3,933    
Goodwill 3,950    
Total assets 9,493    
Deferred income from the company and others 1,945    
Deferred taxes 80    
Fair value of convertible loan from the company 892    
Non-controlling interests 299    
Other liabilities 1,487    
Total liabilities 4,703    
Total consideration transferred $ 4,790    
Percentage of shares issued 36.40%    
Fair value according of shares issued $ 1,853    
Acquisition date fair value of previously held equity interest $ 2,937